Biological Characteristics and Risk Factors for Prognosis of Myelodysplastic Syndrome / 中国实验血液学杂志

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the biological characteristics and risk factors for prognosis of patients with myelodysplastic syndrome (MDS), to emphatically study the correlation of different chromosome karyotype and immune phenotype with the prognosis of MDS patients.</p><p><b>METHODS</b>All clinical data of 60 patients diagnosed as primary MDS over a period of 5 years were collected and compared. The bone marrow short-term culture and G banding technique were used to analyze the chromosome karyotypes of 60 patients, the flow cytometry was used to detect the immune phenotypes(CD10, CD13, CD15, CD7, CD34, CD117). SPSS 19.0 software was applied to deal with all data, the WHO2008 classification and IPSS-R score were used for grouping of MDS.</p><p><b>RESULTS</b>There were 12 cases of low-risk, and 7 cases of high-risk in 60 patients with MDS; 35 out of 60 patients (58.33%) showed karyotypic abnormalities. The proportion of 5, 7, 8, 20, and Y chromosome abnormality were 22.89%, 20.0%, 17.14%, 11.43% and 5.71%, respectively, complex chromosome karyotype accounted for 14.29%. The percentage of normal karyotype transformed into leukemia was 8.0%, the percentage of other abnormal karyotype transformed into leukemia respectively was 80% for complex karyotype, 66.67% for 8 chromosome abnormality, 71.43% for 7 chromosome abnormality, 75.0% for 5 chromosome abnormality. The expression rate of immature myeloid cell surface antigen markers(CD13, CD33, CD117) in high-risk group of patients with MDS significantly higher than that in low-risk group(P<0.05). And the expression rate of mature myeloid cell surface antigen markers (CD15) in high-risk group was significantly lower than that in low-risk group(P<0.05). The expression rate of lymphoid cell surface antigen markers (CD7, CD10) in high-risk group was lower than that in low-risk group(P<0.05).</p><p><b>CONCLUSION</b>Chromosome karyotypes and immune phenotypes have great influence on the prognosis of patients with MDS.</p>